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Bioequivalence (BE) studies are scientific methods that allow
comparison of different medicinal products containing the same active
substance, or different batches of the same medicinal products or, in
a broad sense, different routes of administration of the same product.
Actually, legislation on generic drugs and bioequivalence only exist in
Brazil for drugs intended for human purposes. In the field of
Veterinary Medicine, BE is being used in many countries as part of
the necessary requirements for registration of animal health products,
i.e., to provide efficacy and safety animal data and to allow consumers
safety; indeed, they also assure the quality of the food derived from
treated animals. The present manuscript was designed to review and
discuss BE; for that, it was divided into three major parts: 1-
understanding bioequivalence: importance of BE studies for animal
and human health; 2- type of BE studies included; 3- general









Bioequivalence (BE) studies are
scientific methods designed to compare
different health products containing the same
active constituent or different batches of the
same veterinary medical products, based on
their formulation, pharmacokinetic and
pharmacodynamic properties and residual
profiles in the tissues of  treated animals.1,2,3
BE studies are used in a variety of situations,
most often when a sponsor proposes
manufacturing a generic version of an
approved off-patent product. A BE study
may also be part of a new animal drug
application (NADA) or supplemental
NADA for approval of  an alternative
dosage form, new route of  administration,
or a significant manufacturing change which
may affect drug bioavailability. In veterinary
medicine, BE studies are necessary and
relevant because they allow the establishment
of the necessary requirements for registration
of generic animal health products that ensure
animal and food safety for human being.
Actually, legislation on generic drugs
in Brazil exists only for those to be used in
humans; as a consequence, specific rules for
bioequivalence (BE) studies on veterinary
products are still lacking.  In this regard,
legislation on both generic drugs and BE in
veterinary medicine are being employed and
might be found in many countries.1,2,3
Consideration on such maters seems
appropriate and necessary; indeed, it may
become a useful instrument for governmental
authorities, pharmaceutical industries and
veterinary professionals’ managements in this
field.  The present manuscript was them
designed, to discuss BE; it was divided into
three major parts: 1- understanding
bioequivalence: importance of BE studies
for animal and human health; 2- type of BE
studies included; 3- general consideration on
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experimental design involved o BE studies.
Understanding BE: importance
for animal and human health
Veterinary pharmaceutical product is
a finished dosage form that contains the
pharmacologically active substance(s) with
or without excipient(s). Changes in active
substance purity or in excipients in a
veterinary medical product as well as in the
manufacturing process may have significant
effects on bioavailability.
It is scientifically valid to assume that,
if an active substance or therapeutic moiety
of a test animal health product reaches the
systemic circulation with the same rate and
extent as the active substance or therapeutic
moiety of a reference animal health product,
the local availability (concentration in tissue)
of the active substance or therapeutic moiety
will be similar for the test and reference
products. The similarity of  availability at the
site(s) of action is the basis of concluding
therapeutic equivalence of  the products.
However and importantly, it is usually
accepted that tissue residue depletion of the
generic product is not adequately addressed
through BE studies. For that, sponsors of
drug products for food-producing animals
are generally requested to include BE and
tissue residue studies in their data package.2,3
The in vivo BE of an animal health
product is demonstrated if the rate and
extent of  absorption, as determined by
comparison of measured parameters
derived from relevant data (e.g.
concentration of the active substance in the
blood or pharmacological/clinical effects)
do not indicate a biologically relevant
difference in the rate and extent of
absorption from the reference product. In
other words, two products are considered
to be bioequivalent when they are equally
bioavailable; that is, equal in the rate and
extent to which the active ingredient(s) or
therapeutic ingredient(s) is (are) absorbed and
become(s) available at the site(s) of drug
action.1,2,3
As a general rule, the proposed
generic product should be tested for BE
against the original pioneer product.
However, if the original pioneer product is
no longer marketed, but remains eligible to
be copied, then the first approved and
available generic copy of the pioneer should
be used as the reference product for BE
testing against the proposed new generic
product.2 If  several approved NADA’s exist
for the same drug product, and each
approved product is labeled differently (i.e.,
different species and/or claims), then the
generic sponsor is asked to clearly identify
which product label is the intended pioneer2.
BE testing should be conduct against the
single approved product which bears the
labeling that the generic sponsor intends to
copy.
Thus, a generic animal health drug
may be defined as a product that contain
the same active ingredient, in the same dose
range, in the same pharmaceutical
formulation and that is administered to the
same animal species, for the same route and
for the same therapeutic/prophylactic/feed
addictive purposes. For that, they present the
same efficacy, same security for animal and
human health and, the same quality of the
reference standard, as statically proven by BE
and by tissue depletion residue studies.
According to the Australian Pesticides
& Veterinary Medicines Authority -
APVMA1- a proposed product is considered
to be generic to a reference product if: 1-
ingredients are of  equivalent pharmaceutical
compendial standard, and 2- the active
constituents are the same substances and are
within ± 5% of that in the reference product
or the dose range to the animal is within ±
5% of the reference product, and 3- the non-
active constituents are the same substances
and are within ± 5% of that in the reference
product, except for those constituents
defined in the Australian Guidelines on
Minor Formulation Changes, where they can
vary more than ± 5%, and 4- the product is
in the same dosage form, and finally 5- the
product has the same physico-chemical
properties as the reference product (including
pH, particle size, crystal form, and dissolution
profile where applicable).
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Type of BE studies included
BE can be demonstrated in vivo or,
under specific conditions, in vitro. Figure 1
depicts the more relevant studies related to
BE determination. The best approach
would be that one that uses all methods
available to display BE, i.e., that employs
both in vitro and in vivo methods. However
and in particular terms, the blood level study
is generically preferred above all others being
considered, since it is considered the most
sensitive measure of  BE. For that, the
sponsor should provide justification for
choosing either a pharmacologic or clinical
end-point study over a blood-level (or other
biological fluids or tissues) study.  It should
be noted, however, that tissue residue
depletion studies were also included in this
figure; this was done because, as already
stated, it is usually accepted that tissue residue
depletion of a generic product is not
adequately addressed through BE studies.
In vivo BE studies must be conducted
using the most accurate, sensitive and
reproducible approach. It may be
determined by one of  several direct or
indirect methods. Selection of  the method
depends upon the purpose of  the study, the
analytical method available, and the nature
of the drug product. BE testing should be
conducted using the most appropriate
method available for the specific use of the
product. A classification of such approaches
proposed by the EMEA Committee for
Veterinary Medical Products in descending
order of  accuracy, sensitivity and
reproducibility2 is listed bellow:
a) In vivo testing in target species in
which the concentration of the active
substance or therapeutic moiety or its
representative metabolite(s) in blood, plasma,
serum or if justified, other biological fluid
or appropriate tissues is measured as a
function of time. Reliance on in vivo BE data
relies upon an assumption that the measured
concentrations of active substance have
meaning with respect to the objective of the
trial and the intended label claim. It also
necessitates that adequate drug concentrations
are achieved to allow for the determination
of product concentration vs time profile in
the blood or other biological fluid.
b) In vivo testing in target species in which
an appropriate acute pharmacological/clinical
effect of the active substance or therapeutic
moiety or its metabolite(s) is measured as a
Figure 1 - Studies implicated in bioequivalence determination. Note that equivalence between a generic and a
pioneer product should be obtained using in vitro pharmaceutical equivalence and/or in vivo tests such
as the blood level, the pharmacological and clinical end-points studies. Note also that residue depletion
studies are also necessary
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function of time. This approach can be used
when analytical methods are not available.
Its use requires demonstration of dose-
related response. For veterinary medical
products intended for local effect,
pharmacological/clinical end-points can be
the most relevant approach for the
demonstration of BE.
According to FDA BE Guidance for
Industry3, when absorption of the drug is
sufficient to measure drug concentration
directly in the blood (or other appropriate
biological fluid or tissues) and systemic
absorption is relevant to the drug action, then
a blood (or other biological fluid or tissue)
level BE study should be conducted.
However, when the measurement of the rate
and extent of absorption of the drug in
biological fluids can not be achieved or is
unrelated to drug action, a pharmacologic
end-point (i.e., drug induced physiologic
change which is related to the approved
indications of use) study may be conducted.
Lastly, and in order of  preference, if  drug
concentration in blood (or fluids or tissues)
are not measurable or are inappropriate, and
there are no appropriate pharmacologic
effects that can be monitored, then a clinical
end-point study may be conducted,
comparing the test (generic) product to the
reference (pioneer) product and a placebo
(or negative) control.
Finally, In vitro equivalence studies
could support in vivo BE studies in the
following case2:
a) In vivo BE has been demonstrated
for the highest dosage strength and in vitro
dissolution data is used to support the BE
of the lower dosage strengths for that generic
formulation. In these cases, the use of  in vitro
methods requires that the following
conditions are all met: 1- the dosage strengths
differ only by the mass of the active
substance; 2- the drug is known to be
associated with linear pharmacokinetics; 3-
the composition of  all formulations are
qualitatively identical; 4- the ratios between
active substances of the test- and reference
products are identical.
b) In vitro comparability might be
adequate to confirm the comparability of
the reference product and its generic product
to be administered orally. This applies
particularly to immediate release oral dosage
forms that are rapidly dissolving and contain
drug substances that are both highly soluble
and high permeable.
c) There is a very minor formulation
change to an approved product (or a minor
pre-approval change to a product that has
undergone extensive clinical trials), and has
been determined that the change requires
only in vitro confirmation of  comparability
to the formulation that underwent the
clinical trials.
d) Ensuring batch to batch consistency
within a product.
It should be noted, however, that the
Australian Guidelines on BE1 states that for
certain dosage forms (intravenous solutions,
oral solubilized forms, topical dose forms,
non-absorbed antacids and radio opaque
media and oral tablets), an applicant may
wish to address BE by providing in vitro data
demonstrating pharmaceutical equivalence of
a ´product to a reference product. In this
case, such data should include: 1- nature of
dosage form; 2- solubility of  active
constituent(s) in water; 3- relevant
pharmaceutical characteristics including
particle size, crystal form, and dissolution
profile where applicable; 4- rate limiting steps
in absorption of  the active constituent(s) e.g.
disintegration, dissolution, gut absorption
where applicable or in access to the site of
effect; and 5- relevant scientific argument
regarding clinical consequences of
inequivalence.
General consideration on
experimental design involved on BE
determination
As depicted in Figure 1, BE can be
demonstrated in vivo or, under specific
conditions, in vitro.
In vivo BE studies
BE may be demonstrated in vivo by
one of  several direct or indirect methods. In
descending order of sensitivity: blood levels
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studies, pharmacological end-point studies
and clinical end-point studies. As stated
before, the selection of the method is linked
to the purpose of  the study, the analytical
method available and, among many other
variables, the nature of the product analyzed.
Basic principles
In vivo BE studies usually involve an
experimental part conducted in the field,
where the active substance or therapeutic
moiety are given to the target animal species,
an analytical part where the active substance(s)
or its representative metabolite(s) are
analyzed in the blood, plasma, serum or
other biological fluids or appropriate tissues
and a statistical part. Figure 2 depicts these
parts, the main steps they involve and the
quality compliance test protocols that should
be employed in each of them.
Veterinary Good Clinical Practice
(GCP) should be used in all blood level,
pharmacological end-point, clinical end-
point and residue depletion studies if the
products intendment is food-producing
animals use. The global requirements
referred to as VICH-GCP guidelines4 are
usually employed in the field experiments,
because they were specially prepared to
ensure the accuracy, integrity and correctness
of the obtained data. VICH is a tripartite
(EU, Japan and USA) programme aimed at
harmonizing technical requirements for
veterinary product registration. Its full title is
the International Cooperation on
Harmonization of  Technical Requirements
for Registration of  Veterinary Medical
Products.
Some relevant extracts from the
VICH- GCP guidelines4 are: 1- the
investigator responsible for the study should
have sufficient knowledge, scientific training
and experience, as evidenced by a current
curriculum vitae and other credentials, to
conduct clinical studies to investigate the
effectiveness and in-use safety of
investigational veterinary products in the
target species; 2- the investigator should
delegate authority and work only to
individuals qualified by training and
experience to perform the assigned duties;
3- the field experiment should comply with
the study protocol, being conducted
according to GCP and applicable regulatory
requirements; 4- the equipment and facilities
used to conduct the study should be
adequate and well-maintained; 5- the
housing, feeding, and care of all animals at
the study site should be carefully supervised;
6- all data should be collected and recorded,
including unanticipated observations, in
accordance with the study protocol and
applicable regulatory requirements in an
unbiased manner that accurately and
completely reflects the observations of  the
study; 7-  the investigator should ensure that
Figure 2 - The three different steps of bioequivalence studies. Note the requirements on quality compliance applied
to each of them
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all specimens required to be retained by the
study protocol and any applicable regulatory
requirements are identified in a manner that
is complete, accurate, legible and precludes
loss of identification from the specimen; 8-
the special analysis and/or tests to be
performed including the time of  sampling
and interval between sampling, storage of
samples, and the analysis of testing should
be carefully described; and, among others,
9- all study documentation should be securely
stored for the period of time required by
the relevant regulatory authorities, being
protected from deterioration.
To ensure VICH-GCP, selected
animals for BE studies must be from the
target population for which the product is
intended. Ordinarily, BE studies should be
conducted with health animals representative
of the species, class, gender, breed, age,
weight, hormonal, nutritional and
physiological maturity for which the drug
was approved. Where possible, it is advisable
to restrict the studies to the gender for which
the pioneer product is approved, unless there
is known interaction of  formulation with
gender.  An attempt should be made to
restrict the weight of the test animals to a
narrow range and animals should not receive
any medication prior to testing for a period
of two weeks or more, depending upon the
biological half-life of  the ancillary drug.
Feeding may either enhance or
interfere with drug absorption, depending
upon the characteristics of the drug and the
formulation. Feeding may also increase the
inter- and intrasubject variability in the rate
and extent of drug absorption. The rationale
for conducting each bioequivalence study
under fasting or fed conditions should be
provided in the protocol. In this respect, the
protocol should describe the diet and feeding
regime which will be used in the study.
However, and importantly, if  a pioneer
product label indicates that the product is
limited to administration either in the fed or
fasted state, then the BE study should be
conducted accordingly.
Concerning the analytical part of the
BE studies, it should be conducted and
reported in conformity with the international
principles of GLP and quality compliance
methods. Specifically, it should be conducted
in accordance with requirements stated in the
32nd, 47th and 52nd meetings of the Joint
FAO/WHO Expert Committee on Food
Additives (JECFA)5 or with the European
Community legislation reported in Directives
87/18/EEC and 88/320/EEC. The FDA
considerations included on Assay methods
specified in the BE Guidance to Industry
document3 and the VICH guideline GL1
Validation of  analytical procedures (CVMP/
VIVH/97/076) might also be useful.
In this respect, it’s undisputable that a
properly validated assay method is pivotal
to the acceptability of  any pharmacokinetic
study. For that, the submission should contain
adequate information necessary for the
reviewer to determine the validity of  the
analytical method used to quantitate the level
of the drug under study in the biological
matrix (e.g., blood or tissues). Thus, the
following aspects should be addressed in
assessing method performance: 1-
concentration range and linearity, defined by
at least five concentrations; 2- limit of
detection (LOD), estimated as the response
value calculated by adding three times the
standard deviation of the background
response to the average background
response; 3- limit of quantification (LOQ),
at least ten times the standard deviation of
the background response to the average
background response; 4- specificity,
demonstrated by the analysis of six
independent sources of control matrix; 5-
accuracy (recovery), based upon the mean
value of six replicate injections, at three dose
levels (high, mid-range and LOQ); 6-
precision, evaluated using at least three
known concentration of analyte freshly
spiked in control matrix; 7- analyte stability,
determined with incurred analyte in the
matrix of dosed animals in addition to
control matrix spiked with pure analyte; 8-
analytical system stability, to assure that the
system used remains stable over the time
course of the assay;  9- quality control (QC)
samples, to assure that the complete analytical
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method, sample, preparation, extraction,
clean-up, and instrumental analysis was
performed according to acceptable criteria;
10- replicate and repeat analysis, determined
prior to running the study and recorded in
the method protocol.
Finally, Good Statistical Practice (GSP)
is necessary to analyze the obtained data and
to allow their interpretation.6
Blood level studies
These studies are the most sensitive
measures of  BE. They are performed when
absorption of the drug is sufficient to
measure drug concentration directly in the
blood and systemic absorption is relevant
to the drug action.1,2,3 These studies compare
a test (generic) product to a reference
(pioneer) product using parameters derived
from the concentrations of the drug moiety
and/or its metabolites, as a function of time,
in whole blood, plasma, serum (or in other
appropriate biological fluids or tissues).
Generally, the study should encompass the
absorption, distribution, and depletion
(elimination) phases of the drug
concentrations vs time profiles.
The potency of the pioneer and
generic products should be assayed prior to
conducting the BE study to ensure
compendial specifications are met. FDA
authorities recommend that the potency of
the pioneer and generic lots should differ
by no more than ± 5% for dosage
products3. The animals should be dosed
according to the labeled concentration or
strength of the product, rather than the
assayed potency of the individual batch (i.e.,
the dose should not be corrected for the
assayed potency of the product). The BE
data or derived parameters should not be
normalized to account for any potency
differences between the pioneer and
generic lots.
A single dose study at the highest
approved dose will generally be adequate
for the demonstration of BE. However, a
multiple dose study may be appropriate when
there are concerns regarding poorly
predictable drug accumulation, (e.g., drug
with nonlinear kinetics) or a drug with a
narrow therapeutic window. A multiple dose
study may also be needed when assay
sensitivity is inadequate to permit drug
quantification out to three terminal
elimination half-lives beyond the time when
maximum blood concentrations (CMAX)
are achieved, or in cases where prolonged
or delayed absorption exist.
Figure 3 exemplifies a time vs. plasma
concentration curve. As depicted, the pivotal
parameters for BE estimation on blood level
studies are: CMAX, the maximal
concentration or peak concentration achieved
by the drugs under test in plasma; TMAX
the corresponding time to reach CMAX and,
area under the time vs. concentration curve
AUC(0-t).
As presented in figure 3, the rate of
absorption will be estimated by the
maximum observed drug concentration
(CMAX) and the corresponding time to
reach this maximum concentration (TMAX).
By another way, the extent of  product
bioavailability is estimated by the area under
the blood or plasma concentration vs. time
curve (AUC). AUC is most frequently
estimated using the linear trapezoid rule.
Other methods for AUC estimation may be
proposed in the study protocol and should
be accompanied by appropriate literature
references. In the case a multiple dose BE
study is used, the AUC should be calculated
over one complete dosing interval AUC(0-t).
For a single dose BE study, AUC
should be calculated from time 0 (predose)
to the last sampling time associated with
quantifiable drug concentration AUC(0- LOQ).
The comparison of the test and reference
product value for this noninfinitive estimate
provides the closest approximation of the
measure of uncertainty (variance) and the
relative bioavailability estimate associated with
AUC(0- inf), the full extent of  product
bioavailability7. However, because of the
possibility of multifunctional absorption
kinetics, AUC can not always be determined
when the available drug has been completely
absorbed. Therefore, it is generally accepted
that the duration of sampling should be
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extended until such a time that AUC(0-LOQ)/
AUC(0-inf) > = 0.80. For that, the sampling
times should extend to at least three multiple
of  the drug’s apparent elimination half-life,
beyond the time when CMAX are reached.
Further detail on this subject might be found
elsewhere.8,9
Other relevant pharmacokinetic
measures that should also be part of BE
studies (but preclude statistical comparison
between the pioneer and the drug under test)
are: apparent volume of distribution (Vd),
elimination half-life (t1/2) and depuration or
clearance (D). Vd is a measure that links the
quantity of drug within the organism (the
dose administered) and its concentration in
the plasma (C). The elimination half-life (t1/
2) of a drug is the time necessary to reach
50% of  CMAX.  Finally, the capacity of  an
organism to eliminate a drug is measured by
its clearance that is obtained multiplying the
apparent volume of distribution (Vd) by the
drug’s constant of  elimination (Ke). The
following formulas might be used to
calculate those values.10
In general, product BE should be
based upon total (free plus protein bound)
concentrations of the parent drug (or
metabolite, when applicable). However, if
nonlinear protein binding is known to occur
within the therapeutic dosing range (as
determined from literature or pilot data),
then both the free and total drug
concentrations for the generic and pioneer
products should be included. Similarly, if  the
drug is known to enter blood erythrocytes,
the protocol should address the issue of
potential nonlinearity in erythrocyte uptake
of the drug administered within the labeled
therapeutic dosing range.3
The total number of sampling times
necessary to characterize the blood level
profiles will depend upon the curvature of
the profiles and the magnitude of variability
associated with the bioavailability data
(including pharmacokinetic variability, assay
error and interproduct differences in
absorption kinetics). Anyway, the sampling
Figure 3 - Pivotal parameters analyzed in a Blood Level Study of Bioequivalence. CMax is the maximal concentration
or peak concentration in the blood, TMax the corresponding time to reach CMax and AUC(0-t) the area
under the time vs. concentration curve
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times should adequately define peak
concentration(s) and the extent of
absorption. As stated, it is generally assumed
that the sampling times should extend at least
three terminal elimination half-lives beyond
TMAX, as stated above.
Usually, maximum sampling time
efficiency is achieved by conducting a pilot
investigation. In this case, the pilot study
should identify the general shapes of the test
and reference curves, the magnitude of  the
difference in product profiles, and the noise
associated with each blood sampling time
(e.g. variability attributable to assay error and
the variability between subjects, for parallel
study designs, or within subjects, for
crossover designs). This information should
be applied to the determination of  an
optimum blood sampling schedule. Further
information on this subject might be found
elsewhere.11
Pilot studies are also recommended
as a means of estimating the appropriate
number of subjects to be used, i.e., the
sample size for pivotal BE study.
Furthermore, this number depends on
several factors including variance of the
response, differences in the two formulations
and level of  the rejection of  the hypothesis.
Estimated sample size will vary depending
upon whether the data are analyzed on a log
or linear scale. Useful references on sample
size estimates might be found elsewhere.6,12
A two-period cross-over design is
commonly used in blood level studies. The use
of cross-over designs eliminates a major
source of study variability: between subject
differences in the rates of drug absorption,
drug clearance, and the volume of drug
distribution. Crossover design has advantages
in terms of  power and number of  animals
needed. In a typical two period cross-over
design, subjects are randomly assigned to either
sequence A or sequence B with the restriction
that equal numbers of subjects are initially
assigned to each sequence. The design should
be as follows:
However, a one-period parallel design
may be preferable in the following
conditions: 1- the drug induces physiological
changes in the animal (e.g. liver microssomal
enzyme induction); 2- the drug has a very
long terminal elimination half-life; 3- the
duration of the washout time for the two-
crossover study is too long; and, 4- the drug
follow a delayed or prolonged absorption.
Anyway, when using a cross–over study, the
washout period should be sufficiently long
to allow the second period of the study to
be applicable in the statistical analysis.
Concerning the statistical analysis, the
use of  90% confidence intervals is usually
taken as the best available method for
evaluating BE study.1,2,3,10,13 Thus, two
products are considered to be equivalent
when the 90% confidence intervals found
for the reasons AUCGeneric/AUCPioneer and
CMAXGeneric/CMXPioneer are within 80% and
120% or when generic and pioneer data are
not different from each other at P<0.05.
Further data on statistical analysis of blood
level BE studies might be found
elsewhere.6,13,14
Pharmacological end-point studies
Where the direct measurement of the
rate and extent of absorption of the new
animal drug in biological fluids is
inappropriate or impractical, the evaluation
of  a pharmacologic end-point related to the
labeled indications for use is normally
acceptable. These studies may be conducted
analyzing the physiological changes induced
by the test drug and the reference or pioneer
product.2,3
Typically the design of  a pharmacologic
end-point study should follow the sane
general considerations as the blood level
studies. However, specifics such as the
number of subjects or sampling times will
depend on the pharmacologic end-point
monitored. The parameters to me measured
will also depend upon the pharmacologic
end-points and may differ from those used
in blood level studies. As with blood level
studies, when pharmacologic end-point
studies are used to demonstrate BE, a tissue
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residue study will also be required in food-
producing animals.
For parameter which can be measured
over time, a time vs effect profile is generated,
and equivalence is statistically determined with
a method of analysis that is essentially the
same as for the blood level BE study. Thus,
the use of  90% confidence intervals is usually
taken as the best available method for
evaluating the obtained data. For
pharmacologic effects for which effects vs
time curves can not be generated, then
alternative procedures for statistical analysis
should be discussed and justified in the
experimental study protocol.
Clinical end-point studies
If measurement of the drug or its
metabolites in blood, biological fluids or
tissues is inappropriate or impractical, and
there are no appropriate pharmacological
end-points to monitor (e.g., most production
drugs and some coccidiostats and
antihelmintics), then well-controlled clinical
end-point studies are acceptable for the
demonstration of BE.3 In this case, a parallel
group design with three groups should be
used. The groups should be a placebo (or
negative control), a positive control
(reference/pioneer product) and the test
(generic) product. The purpose of the
placebo (or negative control) is to confirm
the sensitivity or validity of  the study.
Some clinical end-point studies,
however, may not include a placebo (or
negative control) for ethical and/or practical
considerations. If  a placebo is omitted, then
the response(s) to the test and reference
products should each provide a statistically
significant improvement over baseline.
Clinical end-point studies should be
conducted using the target animal species,
with consideration for the sex, class, body
weight, age, health status, and feeding and
husbandry conditions, as described on the
pioneer product labeling. The dosage(s)
approved for the pioneer product should
be used in this study. Finally, the length of
time that the study is conducted should also
be consistent with the duration of use on
the pioneer product labeling. As with other
studies, when clinical end-point studies are
used to demonstrate BE, a tissue residue
depletion study will also be required in food-
producing animals.
In general, the response(s) to be
measured in a clinical end-point study should
be based upon the labeling claims of the
pioneer product. In this respect, it may not
be necessary to collect data on some
overlapping claims (e.g., for a feed additive
which is added as the same amount per ton
of feed for both growth rate and feed
efficiency, data from only one of  the two
responses need to be collected).
Statistical analysis should be used in
clinical end-point studies, to compare the test
product and the reference product.
However, a traditional hypothesis test should
be performed before, comparing both the
test and the reference products separately to
the placebo (or negative control). The
hypothesis test is conducted to ensure that
the study has adequate sensitivity to detect
differences when they actually occur. If  no
improvement (a = 0.05) is seen in parameter
(i.e., the mean of the test and the mean of
the reference products are each not
significantly better than the mean of the
placebo (or negative control), the study
should be considered inadequate to
evaluate BE.
Assuming that the test and reference
products have been shown to be superior
to the placebo (or negative control), the
determination of  BE is based upon the
confidence interval of  the difference
between the two products. The use of  90%
confidence intervals is usually taken as the
best available method for evaluating clinical
end-point data.
If the results are ordered categorical
data (e.g., excellent, good, fair or poor), a
non-parametric hypothesis test of no
difference between test product and placebo
(negative control) and between the reference
product and the placebo (or negative
control) should be performed. As above, if
these tests result in significant differences
between the test product and the negative
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control and the reference product and
negative control, then a non-parametric
confidence interval on the difference
between the test and the reference products
is calculated. Another acceptable approach
for categorical data is to calculate the
confidence interval on the odds ratio
between the test and reference products after
showing that the test and the reference
products are significantly better than the
control. Further detail on statistical analysis
of clinical end-point data might be found
elsewhere.13
Tissue residue depletion studies
The panel on Human Food Safety at
the 1993 Veterinary Drug BE Workshop
addressed tissue residue depletion studies for
generic animal drugs13. As stated many times
before in the present document, the center
has concluded that in addition to BE study,
a tissue residue depletion study should be
conducted for approval of a generic animal
drug product in food producing species.
Indeed, two drug products may have the
same plasma disposition profile at the
concentrations used to asses product BE, but
may have different tissue disposition kinetics
when followed out to the withdrawal time
for the pioneer product. Therefore, to show
the withdrawal period at which residues of
the generic product will be consistent with
the tolerance for the pioneer product, a tissue
residue depletion study is necessary.1,2,3
However, and importantly, for purposes of
calculating a withdrawal period for a generic
animal drug, only the generic product would
be tested (i.e., not the pioneer product), and
only the marker residue in the target tissue
would be analyzed.3
In this respect, it should not be
forgotten, that the results of a BE study or
tissue depletion study in one animal species
can not generally be extrapolated to another
species. Possible species differences in drug
partitioning or binding in tissues could
magnify a small difference in the rate or
extent of drug absorbed into a large
difference in marker residue concentration
in the target tissue. Furthermore, differences
in drug metabolism and excretion are also
known to exist among different food-
producing animals.  Therefore, for a pioneer
product labeled for more than one food-
producing species, a BE study and a tissue
residue depletion study will generally be
requested for each major food-producing
species on the label.1,2,3
Traditional withdrawal studies, as
those described in FAO/WHO Codex
alimentarius guidelines15 are considered the
best design for collecting data for the
calculation of withdrawal periods for drugs
used in food-producing animals. In this
respect, it was not until the 42nd JECFA
meeting that specific requirement for residue
data were presented.5 The committee
requested detailed reports, including
individual animal data, on the followings: 1)
the chemical identity and properties of the
drug; 2) the use and (recommended) doses;
3) pharmacokinetic metabolic and
pharmacodynamic studies in experimental
and food producing animals, and in humans,
where available; 4) residue depletion studies
with radiolabelled drug in target animals from
zero withdrawal time to periods extending
beyond the recommended withdrawal time;
5) information on total residues, including
free and bound residues, and major residue
components to permit selection of  a marker
residue and a target tissue; 6) residue depletion
studies with unlabeled drug for the analysis
of marker residue in target animals and in
eggs and milk; 7) a review of  routine
analytical methods that may be used by
regulatory authorities for the detection of
residues in target tissues; and 8) a description
of the analytical procedure that was chosen
by the sponsor for the detection and
determination of  residues in target tissues
(with sensitivity equal to or less than MRL,
ideally ≤0.5 MRL).
Usually, in these withdrawal studies,
animals are divided into different groups
being slaughtered at carefully preselected
time points following the last (or single)
administration of the test product and
different matrix or target tissue samples are
collected for residue analysis. A statistical
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tolerance limit approach is used to determine
when, with 95% confidence limits, 99% of
treated animals would have tissue residues
bellow the codified limits.
Figure 4 shows an example of this
study; it depicts the depletion of a marker
residue in a given tissue of a food-producing
animal. It is relevant to note that in this curve,
the Maximum Limit of Residue (MLR) is a
point on the curve describing the upper one-
sided 95% confidence limit while the median
is the corresponding point in the regression
line. In other words, the withdrawal time is
correctly defined by the upper one sided
95% confidence limit.
According to international legislation1,2,3,
the generic animal drug will be assigned the
withdrawal time supported by the residue
depletion data, or the withdrawal time
currently assigned to the pioneer product,
whichever is the longer. If  the generic
sponsor wants to request a shorter
withdrawal period for one specific product,
he should provide all data necessary to
support his request, including those that show
no other food safety concerns for the drug
are evident.
Finally, the analytical methodology
used to determine the withdrawal period for
the generic product does not have to be more
rigorous than the approved methodology
used to determine the existing withdrawal
period for the pioneer product. However,
it has to be fully validated and performed
according to GLP and GSP standards, as
stated above. Thus, if an analytical method
other than the approved method is used, the
generic sponsor should provide data
comparing the alternate method to the
approved method.
In vitro pharmaceutical equivalence
A product is considered to have
pharmaceutical equivalence to a reference
product if  the formulation ingredients are
the same and package in a size container made
from identical material.2,3 Specifically, 1-
ingredients in both products should be of
equivalence pharmaceutical compendial
standard; 2- the active constituents should
be the same substance and should be within
± 5% of that in the reference product or
the dose range to the animal should be within
± 5% of the reference product; 3- the non-
active constituents should be the same
substances and should be within ± 5% of
that in the reference product; and 4- the
product should have the same
physicochemical properties as the reference
product.
Figure 4 - Depletion of a marker residue in a given tissue of a food producing animal. Note that in curves like this
one, the Maximum Limit of Residue (MRL) is a point on the curve describing the upper one-sided 95%
confidence limit while the median is the corresponding point in the regression line. Note also that the
withdrawal time is correctly defined by the upper one-sided 95% confidence limit
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Braz. J. vet. Res. anim. Sci., São Paulo, v. 45, suplemento,  p. 5-19, 2008
According to the EMEA guidelines
for the conduct of  BE studies for Veterinary
Medical products2 in vitro BE studies could
support in vivo BE in the following cases: 1-
in vivo BE has been demonstrated for the
highest dosage strength and in vitro
dissolution data is used to support the BE
of the lower dosage strengths for that
generic formulation; 2- in vitro comparability
might be adequate to confirm the
comparability of the reference product and
its generic product to be administered orally;
this applies particularly to immediate release
oral dosage forms that are rapidly dissolving
and contain drug substances that are highly
soluble and highly permeable; 3- there is a
very minor formulation change to an
approved product, and it has been
determined that the change requires only in
vitro confirmation of  comparability to the
formulation that underwent the original trials;
and, 4- ensuring batch to batch consistency
within a product.
According to EMEA guidelines2,
data for in vitro pharmaceutical equivalence
should include: 1- the nature of the dosage
form, the solubility of  the active
constituent(s) in water; 2- the pharmaceutical
characteristics of the product, including
particle size, crystal forms, and dissolution
profile where applicable; 3- information on
rate limiting steps in absorption of the active
constituent(s) e.g. disintegration, dissolution,
gut absorption where applicable or in access
to the site of effect; and, 4- relevant scientific
argument regarding clinical consequences of
inequivalence.
It should be noted, however, that the
in vitro pharmaceutical equivalence test must
be a validated  predictor of the in vivo
dissolution of the product, i.e., the in vitro
test conditions has to have been previously
related to in vivo conditions. An in vitro test
cannot be used when the mean dissolution
time is higher than the mean absorption time.
Moreover, the longer is the dissolution time,
the more difficult will be the extrapolation
between the in vitro and in vivo conditions. It
is therefore not recommended to perform
in vitro test when the dissolution time is too
long. On the contrary, when the process of
dissolution is not the rate limiting step with
respect to the rate and extent of absorption,
the equivalence between the dissolution
profiles of the generic and the reference
products would not be required.
The experimental units collected for
in vitro test are tablets, defined quantities of a
paste, or a powder in a specified packing.
These units should be collected using a
sampling plan, based on a randomization
procedure. This sampling procedure should
be the same for the pioneer formulation and
for the generic formulation, and should be
representative of the entire product
population. Finally, the number of  batches
from which experimental units are sampled
for the in vitro test should be related to the
expected variability between batches.
In vitro pharmaceutical equivalence
should take into account the main sources
of variation, which are likely to influence the
final result: product batch, time of
conservation and apparatus used in the test.
Precautions to avoid bias must be taken, such
as an equal repartition of units of each
formulation in each analytical run.. When
relevant, replicates of measures should be
made, in order to take into account the
variation inherent to the analytical method.
In the case of a study design
comparable to the in vivo BE study design is
relevant, the sample size should be
determined to provide sufficient power in
the demonstration of equivalence. The
residual error (coefficient of variation) used
in the calculation of the sample size should
be obtained from pilot studies, or estimated
from the variance reproducibility of the
analytical method. These points must be
documented in the experimental protocol.
In vitro pharmaceutical data to be
statistically analyzed must be selected a priori
and must be justified with regard to the
correlation with the pharmacokinetic. It
could be sufficient to discuss the relation
between the dissolution time and the
absorption rate for the products compared2.
In vitro BE could be then demonstrated by
comparison of dissolution profiles after
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fitting to a mathematical model or by
comparison of parameters like 50%
dissolution time and 90% dissolution time
and total amount dissolved and AUC.
Statistical analysis could be comparable to
the analysis used in the case of an in vivo BE
study. However, GSP should be employed
and the predetermined equivalence interval
should be carefully justified. It should be kept
in mind that exemptions of in vivo studies
are only possible when results of in vitro
studies could lead to the deduction of similar
pharmacokinetic behavior between the two
products compared.
Conclusion
It is indisputable. High efficiency in
the field of  Veterinary Medicine, particularly
in animal production is achieved when new
technologies are used, quality assurance
methods are always an objective and, animal
health products, such as veterinary medicines
and feed additives, are employed. The use
of animal health products in animal
production however, should be done
following the standards on Good Clinical
Practice (GCP) on Veterinary Drugs Use.
Thus, only products approved for food-
producing animals use and their generic
formulation (that have statistically proven
BE) should be employed. However, the
requirements for in vivo BE study may be
waived for certain products. According to
FDA Guidance to Industry (FDA, 2002)
categories of products which may be eligible
for waivers include, but are not limited to,
the followings: 1- parenteral solutions
intended for injection by intravenous,
subcutaneous, or intramuscular routes of
administration; 2- topically applied solutions
intended for local therapeutic effects.
3- other topically applied dosage forms
intended for therapeutic effects for non-
food animals only; 4- inhalant volatile
anesthetic solutions. For those waivers,
in v i tr o  pharmaceutical equivalence
and residue depletion studies would be
enough to guarantee their registration.
Finally, it is felt relevant to point out again
that in spite of the relevance and the
common use in other countries, BE studies
are still not requested for veterinary
products registration in Brazil.
Estudos de bioequivalência: importância para Medicina Veterinária
Resumo
Os estudos de Bioequivalência (BE) são utilizados para a
comparação de diferentes produtos farmacêuticos que contêm o
mesmo princípio ativo, de diferentes lotes de um mesmo produto
ou, ainda e de uma maneira ampla, de diferentes vias de
administração de um mesmo medicamento. No Brasil dos dias
de hoje, encontramos legislações sobre medicamentos genéricos
e bioequivalência apenas na área de Medicina Humana. No campo
da Medicina Veterinária, os testes de BE têm sido considerados,
em muitos países, como requerimentos necessários para o registro
de produtos destinados aos animais visto que eles asseguram, ao
mesmo tempo, a eficácia do produto, a saúde dos animais tratados
e a qualidade dos alimentos provenientes desses animais. O
presente trabalho faz uma revisão crítica sobre BE. Para tanto, o
assunto foi dividido em três grandes partes: 1- Entendendo a
bioequivalência: importância de estudos de BE para a saúde animal
e humana; 2- tipos de estudos de BE; 3- considerações gerais
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